Floatz logo

AGS-16C3F (ANTI-ENPP3 ANTIBODY)

Carcinoma, Renal Cell

Astellas Pharma Global Development, Inc.antibody_drug_conjugatePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

298 Active assets in the Carcinoma, Renal Cell cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

AGS-16C3F (ANTI-ENPP3 ANTIBODY) is also rated in:

papillary renal cell carcinomaDormant
NR
Indicative ·
/ 100
View asset →
clear cell renal carcinomaDormant
NR
Indicative ·
/ 100
View asset →
Renal Cell Carcinoma With Non-Clear Cell HistologyDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →